Last reviewed · How we verify
NCT06249620
Oral Supplementation With AM3, Hesperidin and Spermidine Supplementation on Immunity Response and Biological Age.
NA trial testing Inmunoferon in Healthy in 41 participants. Completed in 1 October 2022.
11 July 2022
Quick facts
| Lead sponsor | Industrial Farmacéutica Cantabria, S.A. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 41 |
| Start date | 19 April 2022 |
| Primary completion | 11 July 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Inmunoferon
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Industrial Farmacéutica Cantabria, S.A. — full company profile →
Who can join
Adults 29 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this interventional study is to know the immune status of healthy participants and to obtain their biological age before and after two months of ingesting a dietary supplement. These individuals are compared with others who will be given a product of similar appearance, but without containing active components, being the constituents of the placebo group. The study has a duration of 8 weeks, with 2 interventional visits (complete blood samples will be collected) at baseline and at 8 weeks. In order to be included in the trial, the patient must read the Patient Information Sheet and sign the informed consent form. The dosage regimen is two capsules per day in a single dose.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Human Supplementation with AM3, Spermidine, and Hesperidin Enhances Immune Function, Decreases Biological Age, and Improves Oxidative-Inflammatory State: A Randomized Controlled Trial.
Félix J, Díaz-Del Cerro E, Baca A, López-Ballesteros A, et al · · 2024 · cited 2× · PMID 39594533 · DOI 10.3390/antiox13111391
Verify or expand the search:
- PubMed search for NCT06249620
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Industrial Farmacéutica Cantabria, S.A. trials
Trials by the same sponsor.
- NCT06841458 — Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers · NA · recruiting
- NCT06158152 — A Pilot Study to Evaluate the Systemic Effect of Oral Supplementation With AM3 in Patients With Metabolic Syndrome. · NA · recruiting
- NCT06015516 — Bioavailability Clinical Trial of Oral Minoxidil 1 mg · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06249620 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Industrial Farmacéutica Cantabria, S.A.
- Last refreshed: 8 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06249620.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing